We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Today, Aetion announces that it is expanding its relationship with the U.S. Food and Drug Administration (FDA) to use real-world evidence (RWE) to study COVID-19 interventions and advance regulatory science and innovation.
Combines Syneos’ data collection and research services with Aetion Evidence Platform to generate evidence through patient data curation and real-world data.
Aetion and Cegedim Health Data have expanded their collaboration with a new three-year partnership focused on facilitating access to Cegedim’s anonymised real-world data through Aetion’s evidence platform.
Aetion co-authored a study published in Science, which examined lethal coronaviruses SARS-CoV-2, SARS-CoV-1, and MERS-CoV to identify molecular characteristics of potential treatments.